Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

My doctor increased my dose to 1.7 mg of Wegovy instead of 2 mg of Ozempic. I find myself continuing to crave sweets and have gained 8 pounds in around six months. I’m wondering if any studies e ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus ... subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo in adults with obesity.

My doctor increased my dose to 1.7 mg of Wegovy instead of 2 mg of Ozempic. I find myself continuing to crave sweets and have gained 8 pounds in around six months. I’m wondering if any studies e ...